Standard of Care: Protecting Your Bones During Treatment

Because certain medications can weaken bone much faster than the natural aging process, “waiting and seeing” is rarely the best strategy. Standard care focuses on early clinical assessment and personalized intervention to prevent the very first fracture from occurring ^[1][2].

Treatment Thresholds for Steroid Use (GIOP)

The 2022 American College of Rheumatology (ACR) guidelines recommend that adults and children receiving at least 2.5 mg/day of prednisone-equivalent for more than 3 months should have an initial clinical fracture-risk assessment. For those aged 40 or older, this assessment often incorporates FRAX and DXA to determine risk ^[1][3].

Treatment with bone-protecting medication is conditionally or strongly recommended if you fall into certain risk categories:

• Medium, High, or Very High Risk: If your FRAX score, bone density, or fracture history indicates significant risk, medication is typically advised over relying on supplements alone ^[1].
• History of Fracture: If you have already had a fragility fracture, you are generally considered high risk ^[1].
• Initial Choice of Medication: Bisphosphonates (like alendronate or zoledronic acid) and denosumab are common options through shared decision-making. The 2022 guidelines also suggest that anabolic agents (which build new bone, like teriparatide) may be conditionally considered as an initial therapy for selected adults at “high” or “very high” risk ^[1][3].

Thresholds for Cancer Therapies (AIs and ADT)

In cancer care, treatment thresholds vary by guideline and incorporate age, prior fractures, and duration of therapy. The following are examples of how some guidelines approach this:

• AIs (Breast Cancer): Some position statements (like the 2017 Joint AIBL algorithm) recommend considering bone-directed therapy if your T-score is below -2.0, or below -1.5 if you have at least one additional clinical risk factor (like being over age 65 or having a family history of hip fracture) ^[2][4].
• ADT (Prostate Cancer): Treatment is often considered by various guidelines for a prior severe osteoporotic fracture, a T-score below -2.5, or a T-score below -1.5 with additional risk factors ^[5][6].

You should coordinate closely with both your oncology and bone-health teams to decide when intervention is appropriate for you.

The Role of Nutrition and Lifestyle

Lifestyle measures are the foundation of bone health, but for high-risk patients, they are an adjunct (addition) to, not a substitute for, prescription medication ^[7].

1. Targeted Supplementation

Supplements should be tailored to your specific needs, as excess calcium can be harmful for some individuals.

• Vitamin D: A common goal for patients on these medications is a blood level of 50–125 nmol/L of 25-hydroxyvitamin D ^[8]. This often requires a daily supplement of at least 800 IU, guided by your lab results ^[9].
• Calcium: Total calcium needs are typically about 1,000–1,200 mg of elemental calcium daily, depending on age and sex. You should aim to get this from food sources (dairy, leafy greens, fortified foods) and use a supplement only to fill the gap ^[9].
• Protein: Normalizing your protein intake is also recognized as essential for bone health ^[8].

2. Physical Activity and Safety

• Safe Exercise: Working with a physical therapist to incorporate safe weight-bearing, resistance, and balance training helps signal the bones to stay strong and improves walking performance ^[10][7].
• Fall Prevention: Since many medications (like SSRIs or steroids) can cause dizziness or muscle weakness, reducing fall hazards in your home—such as removing loose rugs and improving lighting—is a critical part of fracture prevention ^[8][11].
• Smoking and Alcohol: Avoiding smoking and limiting alcohol consumption are strongly advised, as both can further interfere with bone-building cells and increase fall risk ^[7][12].

Choosing the Right Medication

The choice between medications like denosumab or bisphosphonates depends on your specific needs, kidney function, and cancer status ^[2]. However, if you start denosumab, you must have a plan for a “follow-on” treatment if you ever stop, as discontinuing it can lead to a rapid rebound in bone loss ^[2][4].